BACKGROUND: Despite the high morbidity and mortality of heart failure with preserved ejection fraction (HFpEF), treatment ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Compared with vs DPP4 inhibitors, SGLT2 inhibitors reduce the risk for kidney and ureteral stones in patients with type 2 diabetes, including those with a stone history. Sodium-glucose cotransporter 2 ...

INTERSPECIFIC cell culture contamination has been detected several times by karyotypic and immunological procedures 1–3 ... human cell lines for glucose-6-phosphate de-hydrogenase (G6PD ...

Given the arduous path to drug development, there’s nothing like the joy of bringing an important or even life-saving therapy to market.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License ...

The treatment of acne ( Table I) [1,2,3,4,5,6] is based upon its severity ... patients must have hematologic monitoring. A glucose-6-phosphate dehydrogenase level must be normal before beginning ...

Low magnesium levels are associated with inflammation, insulin resistance (cells do not respond to insulin and have trouble taking up glucose from the blood, causing high blood sugar levels), and ...

On day 2, the patient received 1 litre of intravenous potassium chloride and 2 litres of 5% glucose followed by enteral tube feeding. On day 3, serum phosphate was recorded at 0.33 mol/l and 50 mmol/l ...